Relay Therapeutics (RLAY) Income from Continuing Operations (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Income from Continuing Operations of 79127000.0 for Q1 2026, down 1.49% year-over-year from 80322038.47 in Q1 2025, and down 125.53% quarter-over-quarter from 35085000.0 in Q4 2025.
Powered by 
Analysis
Relay Therapeutics (RLAY) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Income from Continuing Operations for 8 consecutive years, with 79127000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 1.49% year-over-year to 79127000.0; the TTM figure through Mar 2026 stood at 262415000.0 (up 64.77% YoY), while the FY2025 annual figure was 756220000.0, up 1.75% from the prior year.
- Income from Continuing Operations slipped to 79127000.0 in Q1 2026 per RLAY's latest filing, from 35085000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 35085000.0 in Q4 2025 and bottomed at 484867000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 106934294.12 across 5 years, with a median of 82708000.0 in 2024.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 349.31% — and 2025, when it jumped 92.76%.
- Relay Therapeutics' Income from Continuing Operations stood at 75058000.0 in 2022, then plunged by 43.77% to 107913000.0 in 2023, then tumbled by 349.31% to 484867000.0 in 2024, then surged by 92.76% to 35085000.0 in 2025, then sank by 125.53% to 79127000.0 in 2026.
- Business Quant data shows RLAY's Income from Continuing Operations at 79127000.0 in Q1 2026, 35085000.0 in Q4 2025, and 74223000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Relay Therapeutics | 3.85 Bn | 3.85 Bn | - | -83.71 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -83.71 Mn |
| Mar 31, 2026 | -73.29 Mn |
| Dec 31, 2025 | -54.92 Mn |
| Sep 30, 2025 | -73.98 Mn |
| Jun 30, 2025 | -69.74 Mn |
| Mar 31, 2025 | -77.07 Mn |
| Dec 31, 2024 | -76.01 Mn |
| Sep 30, 2024 | -88.10 Mn |
| Jun 30, 2024 | -92.21 Mn |
| Mar 31, 2024 | -81.41 Mn |
| Dec 31, 2023 | -83.50 Mn |
| Sep 30, 2023 | -65.73 Mn |
| Jun 30, 2023 | -98.49 Mn |
| Mar 31, 2023 | -94.24 Mn |
| Dec 31, 2022 | -69.88 Mn |
| Sep 30, 2022 | -84.18 Mn |
| Jun 30, 2022 | -80.50 Mn |
| Mar 31, 2022 | -70.87 Mn |
| Dec 31, 2021 | -69.44 Mn |
| Sep 30, 2021 | -60.83 Mn |